Core Viewpoint - Abivax is experiencing a decline in stock price amid takeover rumors, but management is focused on strengthening its financial position rather than pursuing a sale [1] Group 1: Company Developments - Abivax is preparing for a significant upcoming trial evaluating the long-term maintenance effect of its lead drug candidate, obefazimod, for ulcerative colitis, with nearly 90% of participants having completed the treatment period [2] - The company is on track to report topline results from its ABTECT-UC maintenance trials in late Q2 2026, which is seen as a critical inflection point for the company [3] - Following overwhelmingly positive topline results from previous trials for obefazimod, Abivax's stock experienced a significant increase in July 2025 [4] Group 2: Financial Strategy - CEO De Garidel indicated that Abivax is likely to pursue a mix of equity and debt financing after the trial readout, with funding needs expected to reach several million dollars [5] - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of 530.4 million (approximately $614.42 million), providing a cash runway into Q4 2027 [6] Group 3: Partnership Strategy - Abivax plans to seek commercial partners for markets outside the U.S. following the maintenance data release, given its relatively small size of around 150 employees [7] Group 4: Stock Price Activity - Abivax shares were down 4.83% at $109.84 at the time of publication [8]

Group 1 - A patient treated with Pfizer's hemophilia drug, Hympavzi, died after experiencing serious side effects [1] - The incident occurred as part of a long-term study [1] - Pfizer acknowledged the death and the associated serious side effects [1]

Core Insights - Novo Nordisk's stock has dropped 7.8% to $43.87, reaching a four-year low of $43.37 after disappointing trial results for its Alzheimer's drug, semaglutide [1] - The stock has seen a significant decline of 58% over the past 12 months, following a peak of $148.15 in June 2024 [2] Trading Activity - Call traders are actively engaging with a 10-day call/put volume ratio of 5.75, indicating heightened interest compared to 98% of the past year's readings [3] - A total of 94,000 calls and 62,000 puts have been exchanged today, which is four times the average intraday pace, with the December 39 put being the most popular [4] - Novo Nordisk's options trading tends to outperform volatility estimates, as indicated by a Schaeffer's Volatility Scorecard (SVS) of 87 out of 100 [4]

News of the first successful drug trial in the deadly neurodegenerative disorder Huntington’s is spreading quickly through a cluster of potential patients in northern Scotland. Bloomberg's Prognosis explains why.... https://t.co/2Dop2iAzYt ...